Sagent Pharmaceuticals, a specialty pharmaceutical company, has reintroduced the Irinotecan hydrochloride injection, USP, an antineoplastic agent, in two preservative-free amber glass vials.
According to IMS, for the 12 months ending June 2014, the US market for Irinotecan approximated $23 million. As with all products in Sagent's portfolio, Irinotecan features Sagent's PreventIV MeasuresSM, packaging and labelling, designed to help reduce medication errors.
"We are pleased to be partnering with Jiangsu Hengrui Medicine Co., an injectables leader in China, to launch Irinotecan Hydrochloride Injection, USP," said Jeffrey M. Yordon, chief executive officer and chairman of the Board. "Hengrui was the first injectable plant in China, and Irinotecan was the first injectable product, to receive FDA approval."
Irinotecan hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.